New Cervical Cancer Treatment Reduces Death Risk by 40%
A study reveals significant survival benefits from a revised treatment regimen involving induction chemotherapy before chemoradiation.
Overview
- Researchers at University College London led a decade-long study involving 500 patients from five countries.
- The new regimen involves a short course of chemotherapy before the standard chemoradiation treatment.
- Results show a 40% reduction in death risk and a 35% decrease in cancer recurrence within five years.
- The treatment uses existing, affordable drugs and can be quickly implemented globally.
- Experts urge the widespread adoption of this regimen, highlighting its potential to significantly improve survival rates.